Skip to main content

Table 2 Use of contact precautions by CF center location (in CF centers ≤200 patients)

From: Current infection control practices used in Australian and New Zealand cystic fibrosis centers

 

Australia (n = 15)

New Zealand (n = 14)

Not specified(n = 23)

p-value

Contact precautions

 During hospital admission:

  All people with CF, n (%)

8/9 (89%)

2/5 (40%)

2/10 (20%)

0.007

  MRSA infection, n (%)

14/14 (100%)

9/10 (90%)

14/15 (93%)

0.52

  MRO infection, n (%)

11/11 (100%)

6/7 (86%)

6/10 (60%)

0.030

 During ambulatory care:

  All people with CF, n (%)

5/13 (38%)

0/13 (0%)

2/16 (13%)

0.031

  MRSA infection, n (%)

10/13 (77%)

3/13 (23%)

6/16 (38%)

0.016

  MRO infection, n (%)

10/12 (83%)

1/10 (10%)

2/14 (14%)

< 0.001

  1. CF cystic fibrosis, MRSA methicillin-resistant Staphylococcus aureus, MRO multi-resistant organism (Burkholderia cepacia complex; Mycobacterium abscessus group)